Navigation Links
FDA Approves PREZISTA®/ritonavir Once-Daily Dosing for HIV-1 Treatment-Experienced Adults With No Darunavir Resistance-Associated Mutations
Date:12/13/2010

ODIN study were presented earlier this year at CROI 2010, the 17th Conference on Retroviruses and Opportunistic Infections, in San Francisco. The study achieved its primary objective of demonstrating non-inferiority of PREZISTA/ritonavir once daily compared with twice daily.

PREZISTA Indication: AdultsPREZISTA, co-administered with ritonavir and with other antiretroviral agents, is indicated for the treatment of HIV-1 infection.

This indication is based on analyses of plasma HIV-1 RNA levels and CD4+ cell counts from two controlled, Phase 3 trials of 48 weeks duration in antiretroviral treatment-naïve and treatment-experienced patients, and two controlled, Phase 2 trials of 96 weeks duration in clinically advanced, treatment-experienced adult patients. In treatment-experienced adult patients, the following points should be considered when initiating therapy with PREZISTA/ritonavir:


  • Treatment history and, when available, genotypic or phenotypic testing, should guide the use of PREZISTA/ritonavir.

  • The use of other active agents with PREZISTA/ritonavir is associated with a greater likelihood of treatment response.
  • About the ODIN StudyODIN is a Phase 3b, randomized, open-label study that compared the efficacy, safety, and tolerability of PREZISTA/ritonavir 800/100 mg once daily versus PREZISTA/ritonavir 600/100 mg twice daily at week 48 in 590 treatment-experienced HIV-1-infected adult patients with no DRV RAMs (V11I, V32I, L33F, I47V, I50V, I54L/M, T74P, L76V, I84V, L89V). Patients had HIV-1 RNA greater than 1,000 copies/mL and CD4 count greater than 50 cells/mm(3), and received a stable antiretroviral therapy regimen for greater than or equal to 12 weeks at screening. Patients received either once-daily (n=294) or twice-daily (n=296) PREZISTA/ritonavir plus optimized background regimen. The primary objective of the study was to demonstrate non-inferiority of PREZISTA/ritonavir
    '/>"/>

    SOURCE Tibotec Therapeutics
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
    2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
    3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
    4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
    5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
    6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
    7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
    8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
    9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
    10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
    11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/3/2015)... DUBLIN , June 02, 2015 ... the addition of the "The Future of ... As they are in a desperate need ... and low cost, drug companies have been increasingly ... enhance their productivity while constantly streamlining their internal ...
    (Date:6/3/2015)... 3, 2015  Varian Medical Systems (NYSE: VAR ), world ... cancer, is expanding in the Middle East ... Saudi Arabia . Varian Medical Systems Arabia, the ... was officially launched today at a ceremony attended by local ... "This move represents the next step in our commitment ...
    (Date:6/3/2015)... June 02, 2015 Research and Markets ... the "2015 Strategies in the US Tumor ... Highlights of the Report Include ... tumor marker testing market. , Major issues ... as key economic, regulatory, demographic, social and technological ...
    Breaking Medicine Technology:The Future of Pharmaceutical Outsourcing: 2015 Report 2Varian Establishes Local Entity in Saudi Arabia to Support Expansion in Middle East 2United States Strategies in the Tumor Marker Testing Market 2015 2
    ... May 5, 2011 Novartis Pharmaceuticals Corporation ("Novartis") announced ... approved Afinitor® (everolimus) tablets for the treatment of progressive ... unresectable, locally advanced or metastatic disease(4). This marks the ... in the US in nearly 30 years(5). ...
    ... FRANCISCO, May 5, 2011 Cardiac Network, Inc. (Other OTC: ... a 1-for-750 reverse stock split (the "Reverse Stock Split"). The ... business and trading on May 6, 2011 (the "Effective Date"). ... changed from "CNWI" to "CNWID" for approximately 20 business days, ...
    Cached Medicine Technology:Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 2Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 3Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 4Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 5Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 6Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 7Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 8Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 9Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 10Cardiac Network Announces Reverse Stock Split 2
    (Date:6/3/2015)... A group of nine authors involved with ... Inspire Award at DIA’s upcoming Annual Meeting. DIA’s Global ... their leadership, level of excellence, and commitment to service ... of the Author(s) of the Year Award, which acknowledges ... made a significant impact in advancing medical product development, ...
    (Date:6/3/2015)... 03, 2015 Z-Medica®, LLC, a leading ... June has been designated as National Safety Month by ... AZ. Police Department for its commitment to public safety. ... their Individual First Aid Kits (IFAK) over 100 times ... shootings, stabbings or traffic accidents. Each kit is equipped ...
    (Date:6/3/2015)... June 03, 2015 Researchers at the ... for mesothelioma and say the tried-and-true marker mesothelin is ... an article on the research. Click here to ... National Center for Asbestos Related Diseases say, even though ... it is still preferable to fibulin-3 for identifying mesothelioma. ...
    (Date:6/3/2015)... According to an article published on May14th by ... pills which actually contained the potent addictive drug fentanyl. ... even sported the “A/215” imprint common on real oxycodone ... oxycodone to be exceptionally critical of their prescriptions—especially those ... on the street. Fentanyl is an opiate-based narcotic and ...
    (Date:6/3/2015)... Atlanta, GA (PRWEB) June 03, 2015 ... A in Duluth, GA will celebrate its grand opening ... 2015. , The first prosthetic center of its kind ... and their family unmatched care and outcomes through use ... Keith Watson, CPO & CEO of Fourroux Prosthetics, states, ...
    Breaking Medicine News(10 mins):Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 2Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 3Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 4Health News:Z-Medica Commends Tucson Police Department for Trauma Kit Utilization 2Health News:Analysis Reveals Gold Standard Mesothelioma Biomarker Still the Best, According to Surviving Mesothelioma 2Health News:Fake Oxycodone Pills of Fentanyl Discovered in Tennessee by Police 2Health News:Fake Oxycodone Pills of Fentanyl Discovered in Tennessee by Police 3Health News:Fourroux Prosthetics Atlanta to Have Grand Opening Gala & Ribbon Cutting Ceremony 2
    ... , , WASHINGTON, July 22 There ... (H.R. 3200) that concern citizens who care greatly about the freedom to ... bill: , , * Eliminates Existing Private ... "Acceptable" to the Federal Government, But Is Just Fine With You ...
    ... , , , ... consecutive year, Regence won four bronze (second-place) Telly Awards for originally created ... Web site for Regence members. , , ... of non-news and advertising video production; Regence,s videos were selected from more ...
    ... , SAN DIEGO, July 22 ... it intends to offer, subject to market and other conditions, 9,000,000 ... connection with this offering, Orexigen expects to grant to the underwriter ... of common stock to cover overallotments, if any. All of the ...
    ... , LANCASTER, Pa., July 22 The Board of Directors for Herley ... management leadership. , , , ... Lieberman named Chairman of The Board , Richard Poirier ... Walker (Ret.) to continue as Vice Chairman of the Board , ...
    ... Finding may lead to new treatments, researcher says , WEDNESDAY, ... thrombomodulin, which is involved in blood clotting and preventing cell ... new Canadian study suggests. , The finding might lead to ... about 300 children affected by it in the United States, ...
    ... such program in world started in Australia , WEDNESDAY, ... readying its first human trials of an experimental vaccine ... announced Wednesday. , Two possible vaccines will be tested ... of the National Institute of Allergy and Infectious Diseases ...
    Cached Medicine News:Health News:Mandate for Health Insurance: Inconvenient Truths About How It Will Affect You and Your Family 2Health News:Regence Wins Four Telly Awards for Health and Wellness Videos 2Health News:Orexigen(R) Therapeutics Announces Proposed Public Offering of Common Stock 2Health News:Herley Industries, Inc. Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22, 2009 Conference in New York 2Health News:Herley Industries, Inc. Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22, 2009 Conference in New York 3Health News:Herley Industries, Inc. Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22, 2009 Conference in New York 4Health News:Herley Industries, Inc. Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22, 2009 Conference in New York 5Health News:Gene Mutation Could Be Key to Rare Blood Vessel Disease 2Health News:Gene Mutation Could Be Key to Rare Blood Vessel Disease 3Health News:U.S. Swine Flu Vaccine Trials Set to Begin 2Health News:U.S. Swine Flu Vaccine Trials Set to Begin 3Health News:U.S. Swine Flu Vaccine Trials Set to Begin 4Health News:U.S. Swine Flu Vaccine Trials Set to Begin 5Health News:U.S. Swine Flu Vaccine Trials Set to Begin 6Health News:U.S. Swine Flu Vaccine Trials Set to Begin 7Health News:U.S. Swine Flu Vaccine Trials Set to Begin 8Health News:U.S. Swine Flu Vaccine Trials Set to Begin 9Health News:U.S. Swine Flu Vaccine Trials Set to Begin 10Health News:U.S. Swine Flu Vaccine Trials Set to Begin 11Health News:U.S. Swine Flu Vaccine Trials Set to Begin 12Health News:U.S. Swine Flu Vaccine Trials Set to Begin 13
    ... product solutions were developed to assist in ... To maximize use of existing capital equipment, ... the productivity of their employees, organizations are ... their valuable assets and ensure those assets ...
    ... Mobile Location-ID™ offers a for asset tracking electronically. ... to all the assets that will be tracked. ... equipped with a reader, antenna, and a portable ... small as 10 inches x 6 inches. One ...
    Radianse indoor positioning supports healthcare asset management with a way to locate medical equipment, devices and other portable assets....
    ... provides hospitals with a suite ... all their supplies, drugs, assets, ... remove all manual compliance from ... accurately. iRIS, or Intelligent Radio-Frequency ...
    Medicine Products: